Key result
New oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, require dentists to understand their mechanisms, reversal strategies, and management guidelines during dental treatment.
Population
Patients taking oral anticoagulants who require dental treatment
Design
Review
Authors
Loading...
Urges dentist education on NOAC protocols to minimize bleeding; leaves open prospective validation of management strategies.
Provides guidance for dentists on managing patients taking newer oral anticoagulants.
Thean et al. (2015) conducted a review in Patients on oral anticoagulants requiring dental treatment. New oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Warfarin was evaluated. New oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, require dentists to understand their mechanisms, reversal strategies, and management guidelines during dental treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: